Articles tagged with "patient care"

Basics of Biologic Joint Reconstruction

Andreas Gomoll, MD | April 6, 2012

For young patients especially, this can delay knee replacement and provide better outcomes.

Reflections on Living with Lupus, and on Treating It

Simon M. Helfgott, MD | April 6, 2012

There are some people whose purpose in life is to entertain. Some of us are fortunate to have them as our patients.

The Three-Fold Cord of Rheumatology

Kelly Young | April 6, 2012

How the proverbial three-fold cord applies to rheumatology.

American College of Rheumatology (ACR) Advocates for Improved Access to Critical Treatments

Staff | April 6, 2012

The ACR is promoting federal legislation to eliminate high cost sharing for specialty tier medications in all states.

Dermatology Case: History of ANCA–Associated Vasculitis, Fever, Rash

Joseph F. Merola, MD, Monica Ramirez, MD | April 6, 2012

A 66-year-old woman with a history of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis presents with two days of fever and rash.

Dermatology Case Answer: History of ANCA–Associated Vasculitis, Fever, Rash

Joseph F. Merola, MD, Monica Ramirez, MD | April 6, 2012

A 66-year-old woman with a history of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis presents with two days of fever and rash.

Treatment Patterns and Trends for Spondylarthropathies

Vanessa Caceres | April 6, 2012

Methotrexate is a commonly used disease-modifying antirheumatic drug (DMARD) for treating patients with psoriatic arthritis (PsA). However, is it truly as effective as many think it is? That’s the question raised during the session “Spondylarthropathies: Recent Insights,” which took place at the 2011 ACR/ARHP Annual Scientific Meeting in November.

Rheumatoid Arthritis Drugs May Cut Cardiovascular Risk

Kathleen Louden | April 6, 2012

Other studies at the ACR/ARHP Annual Scientific Meeting in November examined arthritis treatment, scleroderma screening.

Letter: Another Thinking Discipline

Walter Doege, MD | April 6, 2012

I read today the article “How a Rheumatologist Thinks” and I want to say that is one of the most interesting articles I’ve read about clinical medicine.

The Mystery of IVIg

Eveline Wu, MD, Michael M. Frank, MD | March 8, 2012

Although initially given as replacement therapy for patients with primary and secondary immunodeficiency states, intravenous immunoglobulin (IVIg) has proven to be effective in the treatment of various autoimmune and inflammatory disorders. This success has led to a dramatic increase in the use of IVIg, with its use as an antiinflammatory agent now vastly surpassing its use in the treatment of immunodeficiencies. Even so, the basis for the antiinflammatory activity of IVIg remains unclear.